Moderna, Inc. Operating Income
Moderna, Inc. (MRNA) reported Operating Income of -$815.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-31
- Moderna, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$815.00M.
- Moderna, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$1.39B.
- Moderna, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$857.00M.
- Moderna, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$260.00M.
- Moderna, Inc. operating income (loss) for fiscal 2025 was -$3.07B.
- Moderna, Inc. operating income (loss) for fiscal 2024 was -$3.94B.
- Moderna, Inc. operating income (loss) for fiscal 2023 was -$4.24B, a 145.00% decline from fiscal 2022.
- Moderna, Inc. operating income (loss) for fiscal 2022 was $9.42B, a 29.15% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$815.00M 10-Q · filed 2026-07-31 | -$2.20B 10-Q · filed 2026-07-31 | -$3.06B derived: sum of 3 quarters · filed 2026-07-31 | -$3.32B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$1.39B 10-Q · filed 2026-05-01 | -$2.25B derived: sum of 2 quarters · filed 2026-05-01 | -$2.50B derived: sum of 3 quarters · filed 2026-05-01 | -$3.41B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$857.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.12B derived: sum of 2 quarters · filed 2026-02-20 | -$2.02B derived: sum of 3 quarters · filed 2026-07-31 | -$3.07B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | -$260.00M 10-Q · filed 2025-11-06 | -$1.17B derived: sum of 2 quarters · filed 2026-07-31 | -$2.22B 10-Q · filed 2025-11-06 | -$3.46B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$907.00M 10-Q · filed 2026-07-31 | -$1.96B 10-Q · filed 2026-07-31 | -$3.20B derived: sum of 3 quarters · filed 2026-07-31 | -$3.27B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$1.05B 10-Q · filed 2026-05-01 | -$2.30B derived: sum of 2 quarters · filed 2026-05-01 | -$2.37B derived: sum of 3 quarters · filed 2026-05-01 | -$3.73B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$1.25B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.32B derived: sum of 2 quarters · filed 2026-02-20 | -$2.68B derived: sum of 3 quarters · filed 2026-02-20 | -$3.94B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | -$70.00M 10-Q · filed 2025-11-06 | -$1.43B derived: sum of 2 quarters · filed 2025-11-06 | -$2.70B 10-Q · filed 2025-11-06 | -$2.69B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | -$1.36B 10-Q · filed 2025-08-01 | -$2.63B 10-Q · filed 2025-08-01 | -$2.62B derived: sum of 3 quarters · filed 2026-02-20 | -$4.63B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$1.27B 10-Q · filed 2025-05-01 | -$1.26B derived: sum of 2 quarters · filed 2026-02-20 | -$3.27B derived: sum of 3 quarters · filed 2026-02-20 | -$5.14B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$2.01B derived: sum of 2 quarters · filed 2026-02-20 | -$3.87B derived: sum of 3 quarters · filed 2026-02-20 | -$4.24B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | -$2.01B 10-Q · filed 2024-11-07 | -$3.88B derived: sum of 2 quarters · filed 2024-11-07 | -$4.25B 10-Q · filed 2024-11-07 | -$2.67B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$1.87B 10-Q · filed 2024-08-01 | -$2.23B 10-Q · filed 2024-08-01 | -$653.00M derived: sum of 3 quarters · filed 2025-02-21 | $513.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$366.00M 10-Q · filed 2024-05-02 | $1.21B derived: sum of 2 quarters · filed 2025-02-21 | $2.38B derived: sum of 3 quarters · filed 2025-02-21 | $4.83B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $1.58B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.75B derived: sum of 2 quarters · filed 2025-02-21 | $5.19B derived: sum of 3 quarters · filed 2025-02-21 | $9.42B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $1.17B 10-Q · filed 2023-11-03 | $3.61B derived: sum of 2 quarters · filed 2023-11-03 | $7.84B 10-Q · filed 2023-11-03 | $13.25B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $2.45B 10-Q · filed 2023-08-03 | $6.67B 10-Q · filed 2023-08-03 | $12.08B derived: sum of 3 quarters · filed 2024-02-23 | $15.64B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $4.23B 10-Q · filed 2023-05-04 | $9.64B derived: sum of 2 quarters · filed 2024-02-23 | $13.20B derived: sum of 3 quarters · filed 2024-02-23 | $16.26B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $5.41B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $8.97B derived: sum of 2 quarters · filed 2024-02-23 | $12.03B derived: sum of 3 quarters · filed 2024-02-23 | $13.30B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $3.56B 10-Q · filed 2022-11-03 | $6.62B derived: sum of 2 quarters · filed 2022-11-03 | $7.89B 10-Q · filed 2022-11-03 | $7.61B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $3.06B 10-Q · filed 2022-08-03 | $4.33B 10-Q · filed 2022-08-03 | $4.05B derived: sum of 3 quarters · filed 2023-02-24 | $3.82B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $1.27B 10-Q · filed 2022-05-04 | $991.00M derived: sum of 2 quarters · filed 2023-02-24 | $756.00M derived: sum of 3 quarters · filed 2023-02-24 | $634.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | -$275.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$510.00M derived: sum of 2 quarters · filed 2023-02-24 | -$632.00M derived: sum of 3 quarters · filed 2023-02-24 | -$763.00M 10-K · filed 2023-02-24 | -$763.14M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | -$235.00M 10-Q · filed 2021-11-04 | -$235.12M 10-Q · filed 2020-10-30 | -$357.00M derived: sum of 2 quarters · filed 2021-11-04 | -$488.00M 10-Q · filed 2021-11-04 | -$488.11M 10-Q · filed 2020-10-30 | -$618.56M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | -$122.00M 10-Q · filed 2021-08-05 | -$122.13M 10-Q · filed 2020-08-06 | -$253.00M 10-Q · filed 2021-08-05 | -$252.99M 10-Q · filed 2020-08-06 | -$383.56M derived: sum of 3 quarters · filed 2021-08-05 | -$514.32M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$131.00M 10-Q · filed 2021-05-06 | -$130.86M 10-Q · filed 2020-05-07 | -$261.56M derived: sum of 2 quarters · filed 2021-05-06 | -$392.32M derived: sum of 3 quarters · filed 2021-05-06 | -$536.03M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | -$130.56M 10-K · filed 2020-02-27 | -$261.32M derived: sum of 2 quarters · filed 2020-10-30 | -$405.03M derived: sum of 3 quarters · filed 2020-10-30 | -$546.00M 10-K · filed 2022-02-25 | -$545.72M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | -$130.76M 10-Q · filed 2020-10-30 | -$130.86M 10-Q · filed 2019-11-06 | -$274.47M derived: sum of 2 quarters · filed 2020-10-30 | -$416.11M 10-Q · filed 2020-10-30 | -$416.63M 10-Q · filed 2019-11-06 | -$569.14M derived: sum of 4 quarters · filed 2020-10-30 | ||
| 2019-06-30 | -$143.71M 10-Q · filed 2020-08-06 | -$143.94M 10-Q · filed 2019-08-08 | -$285.35M 10-Q · filed 2020-08-06 | -$285.77M 10-Q · filed 2019-08-08 | -$438.38M derived: sum of 3 quarters · filed 2020-08-06 | -$524.20M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$141.64M 10-Q · filed 2020-05-07 | -$141.83M 10-Q · filed 2019-05-09 | -$294.67M derived: sum of 2 quarters · filed 2020-05-07 | -$380.49M derived: sum of 3 quarters · filed 2020-05-07 | -$477.50M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | -$153.03M 10-K · filed 2020-02-27 | -$238.85M derived: sum of 2 quarters · filed 2020-02-27 | -$335.86M derived: sum of 3 quarters · filed 2020-02-27 | -$413.27M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$85.82M 10-K · filed 2020-02-27 | -$182.83M derived: sum of 2 quarters · filed 2020-02-27 | -$260.24M 10-Q · filed 2019-11-06 | -$302.06M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | -$97.02M 10-K · filed 2020-02-27 | -$174.42M 10-Q · filed 2019-08-08 | -$216.25M derived: sum of 3 quarters · filed 2020-02-27 | -$284.12M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | -$77.40M 10-K · filed 2020-02-27 | -$119.23M derived: sum of 2 quarters · filed 2020-02-27 | -$187.10M derived: sum of 3 quarters · filed 2020-02-27 | -$281.30M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | -$41.83M 10-K · filed 2019-03-13 | -$109.70M derived: sum of 2 quarters · filed 2019-03-13 | -$203.89M derived: sum of 3 quarters · filed 2019-03-13 | -$269.36M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | -$67.87M 10-K · filed 2019-03-13 | -$162.06M derived: sum of 2 quarters · filed 2019-03-13 | -$227.53M derived: sum of 3 quarters · filed 2019-03-13 | |||||
| 2017-06-30 | -$94.19M 10-K · filed 2019-03-13 | -$159.66M derived: sum of 2 quarters · filed 2019-03-13 | ||||||
| 2017-03-31 | -$65.46M 10-K · filed 2019-03-13 | |||||||
| 2016-12-31 | -$223.77M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |